These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34169907)

  • 1. Copper-lowering agents as an adjuvant in chemotherapy.
    Kadu P; Sawant B; Kale PP; Prabhavalkar K
    Indian J Pharmacol; 2021; 53(3):221-225. PubMed ID: 34169907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
    Khan G; Merajver S
    Expert Opin Investig Drugs; 2009 Apr; 18(4):541-8. PubMed ID: 19335282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
    Fu S; Hou MM; Wheler J; Hong D; Naing A; Tsimberidou A; Janku F; Zinner R; Piha-Paul S; Falchook G; Kuo MT; Kurzrock R
    Invest New Drugs; 2014 Jun; 32(3):465-72. PubMed ID: 24306314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming platinum resistance through the use of a copper-lowering agent.
    Fu S; Naing A; Fu C; Kuo MT; Kurzrock R
    Mol Cancer Ther; 2012 Jun; 11(6):1221-5. PubMed ID: 22491798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
    Gartner EM; Griffith KA; Pan Q; Brewer GJ; Henja GF; Merajver SD; Zalupski MM
    Invest New Drugs; 2009 Apr; 27(2):159-65. PubMed ID: 18712502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of copper status for cancer therapy.
    Goodman VL; Brewer GJ; Merajver SD
    Curr Cancer Drug Targets; 2005 Nov; 5(7):543-9. PubMed ID: 16305350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
    Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
    J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper in medicine: homeostasis, chelation therapy and antitumor drug design.
    Wang T; Guo Z
    Curr Med Chem; 2006; 13(5):525-37. PubMed ID: 16515519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper in diseases and treatments, and copper-based anticancer strategies.
    Tisato F; Marzano C; Porchia M; Pellei M; Santini C
    Med Res Rev; 2010 Jul; 30(4):708-49. PubMed ID: 19626597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper Depletion as a Therapeutic Strategy in Cancer.
    Lopez J; Ramchandani D; Vahdat L
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.
    Chen HH; Chen WC; Liang ZD; Tsai WB; Long Y; Aiba I; Fu S; Broaddus R; Liu J; Feun LG; Savaraj N; Kuo MT
    Expert Opin Ther Targets; 2015; 19(10):1307-17. PubMed ID: 26004625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Biomedical Use of Copper Chelation Therapy.
    Baldari S; Di Rocco G; Toietta G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper deficiency as an anti-cancer strategy.
    Goodman VL; Brewer GJ; Merajver SD
    Endocr Relat Cancer; 2004 Jun; 11(2):255-63. PubMed ID: 15163301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting copper curbs angiogenesis, studies show.
    Vanchieri C
    J Natl Cancer Inst; 2000 Aug; 92(15):1202-3. PubMed ID: 10922401
    [No Abstract]   [Full Text] [Related]  

  • 16. Overcoming platinum drug resistance with copper-lowering agents.
    Chen HH; Kuo MT
    Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment.
    Gupte A; Mumper RJ
    Cancer Treat Rev; 2009 Feb; 35(1):32-46. PubMed ID: 18774652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics.
    Kalinowski DS; Stefani C; Toyokuni S; Ganz T; Anderson GJ; Subramaniam NV; Trinder D; Olynyk JK; Chua A; Jansson PJ; Sahni S; Lane DJ; Merlot AM; Kovacevic Z; Huang ML; Lee CS; Richardson DR
    Biochim Biophys Acta; 2016 Apr; 1863(4):727-48. PubMed ID: 26844773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
    Kontoghiorghes GJ; Efstathiou A; Ioannou-Loucaides S; Kolnagou A
    Hemoglobin; 2008; 32(1-2):217-27. PubMed ID: 18274999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper metabolism as a unique vulnerability in cancer.
    Shanbhag VC; Gudekar N; Jasmer K; Papageorgiou C; Singh K; Petris MJ
    Biochim Biophys Acta Mol Cell Res; 2021 Feb; 1868(2):118893. PubMed ID: 33091507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.